Noelia Tarazona, Francisco Gimeno-Valiente, Valentina Gambardella, Marisol Huerta, Susana Roselló, Sheila Zuniga, Alexandre Calon, Juan Antonio Carbonell-Asins, Elisa Fontana, Carolina Martinez-Ciarpaglini, Katherine Eason, Pilar Rentero-Garrido, Tania Fleitas, Federica Papaccio, David Moro-Valdezate, Gift Nyamundanda, Josefa Castillo, Alejandro Espí, Anguraj Sadanandam, Desamparados Roda, Andrés Cervantes
BACKGROUND: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into a multimodal approach may improve our accuracy in determining risk of recurrence. METHODS: One hundred and fifty patients consecutively diagnosed with localised CC were prospectively enrolled in our study...
September 2020: ESMO Open